MedTrace Logo

A Dose-Finding Study of Petrelintide With Enicepatide (RO7795068) in Adults With Obesity or Overweight

NCT07589686 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 486

Last updated 2026-05-15

No results posted yet for this study

Summary

The main purpose of this study is to evaluate the safety and efficacy of the co-administration of petrelintide and enicepatide compared with placebo, petrelintide monotherapy, and enicepatide monotherapy in participants with obesity or overweight with at least one weight-related comorbidity.

Conditions

  • Obesity or Overweight

Interventions

DRUG

Petrelintide

Petrelintide will be administered subcutaneously to participants once weekly

COMBINATION_PRODUCT

Enicepatide

Enicepatide will be administered subcutaneously to participants once weekly

DRUG

Petrelintide-matching Placebo

Matching placebo to Petrelintide will be administered subcutaneously to participants once weekly

COMBINATION_PRODUCT

Enicepatide-matching Placebo

Matching placebo to Enicepatide will be administered subcutaneously to participants once weekly

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-30
Primary Completion
2027-11-12
Completion
2028-01-31
FDA Drug
Yes

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07589686 on ClinicalTrials.gov